Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:21:22.494Z.
Consensus retrieved: 2026-10-06T10:32:43.269Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:21:22.494Z.
Quote observation: 2026-10-06T14:20:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3daf5633c8ac25837d6b7f560b0674bc697d9f6607e17ed58c514225f564db96
FORWARD PE RATIO
N/A
Cronos Group Inc.
Market Cap
$1.21B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Cronos Group Inc. (CRON) | $1.21B | N/A |
| Innovage Holding Corp. (INNV)vs › | $1.21B | 20.26 |
| MannKind Corporation (MNKD)vs › | $1.19B | N/A |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.17B | N/A |
| Kardigan, Inc. (KARD)vs › | $1.15B | N/A |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.15B | N/A |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.14B | N/A |
| Harrow Health, Inc. (HROW)vs › | $1.12B | N/A |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.31B | N/A |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.10B | 8.43 |
Trailing P/E
17.9
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
Consensus estimates for this stock are reported in USD, while the share price trades in USD — so per-fiscal-year implied multiples can't be computed honestly here. The analyst estimates table shows the consensus figures with their correct currency label.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
